evidence: It was clear, by the fall of 2020, COVID-19 vaccines could reduce symptomatic COVID-19 and also severe disease against prevailing strain(s) in adults. This finding will be remembered as a seminal moment in medical history, and two of these products rapidly received emergency use authorization (EUA) in the US. Pfizer received EUA on Dec 11, 2020 for ages 16 and up (Pfizer 2020b). Moderna received EUA on Dec 18, 2020 for 18 and up (Mezher 2020) with distribution following soon thereafter. [...] Mezher, M. 2020. FDA issues EUA for Moderna COVID vaccine | RAPS. Regulatory Focus. https://www.raps.org/news-and-articles/news-articles/2020/12/fda-issues-eua-for-moderna-covid-vaccine [...] Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study | Business Wire. 2020. Business Wire. https://www.businesswire.com/news/home/20201116005608/en/Moderna%E2%80%99s-COVID-19-Vaccine-Candidate-Meets-its-Primary-Efficacy-Endpoint-in-the-First-Interim-Analysis-of-the-Phase-3-COVE-Study